SANTARUS INC (SNTS) [Rocket]

Date Filed	Type	Description
05/23/2011	BW	Santarus Announces Presentation of RHUCIN Clinical Data at 7th C1 Inhibitor Deficiency Workshop
05/04/2011	BW	Santarus Reports First Quarter 2011 Financial Results
05/03/2011	BW	Santarus Announces Oral Presentations of Budesonide MMX Phase III Data at Digestive Disease Week Meeting
04/21/2011	BW	Santarus to Hold First Quarter 2011 Financial Results Conference Call on May 4
03/21/2011	MW	Santarus and Pharming announce RHUCIN poster at American Academy of Allergy, Asthma & Immunology 2011 Annual Meeting
03/21/2011	BW	Santarus and Pharming Announce RHUCIN Poster at American Academy of Allergy, Asthma & Immunology 2011 Annual Meeting
03/10/2011	BW	Santarus Initiates Phase I Clinical Study with SAN-300
03/03/2011	BW	Santarus Reports Fourth Quarter and Full Year 2010 Financial Results
03/01/2011	BW	Santarus to Present at March Investment Conferences
02/28/2011	MW	Santarus and Pharming announce receipt of FDA refusal to file letter for RHUCIN Biologics License Application
02/28/2011	BW	Santarus and Pharming Announce Receipt of FDA Refusal to File Letter for RHUCIN Biologics License Application
02/22/2011	BW	Santarus to Hold Fourth Quarter and Full Year 2010 Financial Results Conference Call on March 3
02/22/2011	BW	Santarus and Pharming Announce Initiation of Phase IIIb Clinical Study with RHUCIN in Acute Hereditary Angioedema
02/22/2011	MW	Pharming and Santarus announce initiation of Phase IIIb clinical study with RHUCIN in Acute Hereditary Angioedema
12/28/2010	MW	Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
11/23/2010	BW	Santarus to Present at Piper Jaffray 22nd Annual Health Care Conference
11/15/2010	BW	Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
11/08/2010	BW	Santarus Reports Third Quarter 2010 Financial Results
11/08/2010	BW	Santarus Announces Positive Top-Line Results in E.U. Phase III Clinical Study Evaluating Budesonide MMX in Ulcerative Colitis
11/04/2010	BW	Cycloset Data to Be Presented in Poster Session at 8th Annual World Congress on Insulin Resistance, Diabetes & CVD
10/27/2010	BW	Santarus to Hold Third Quarter 2010 Financial Results Conference Call on November 8
10/21/2010	MW	Pharming announces nine month financial report 2010
09/29/2010	BW	Santarus and Cosmo Announce Positive Top-Line Results in U.S. Phase III Clinical Study Evaluating Budesonide MMX in Ulcerative Colitis
09/13/2010	MW	Pharming signs commercialization agreement with Santarus for Rhucin(R) in North America
09/13/2010	BW	Santarus Adds Two Novel Biologic Drug Candidates to Pipeline
09/09/2010	BW	Santarus to Present at September Investment Conferences
09/08/2010	BW	Santarus Licenses Novel Type 2 Diabetes Drug CYCLOSET
08/30/2010	BW	Santarus Extends Maturity of $25 Million Revolving Line of Credit to July 2013
08/02/2010	BW	Santarus Reports Second Quarter 2010 Financial Results
07/26/2010	BW	Santarus to Hold Second Quarter 2010 Financial Results Conference Call on August 2
06/30/2010	BW	Santarus Announces Launch of Prescription ZEGERID Authorized Generic and Company Restructuring
05/06/2010	BW	Santarus Reports First Quarter 2010 Financial Results